-

Pfizer Declares Third-Quarter 2023 Dividend

Board of Directors approves quarterly cash dividend of
$0.41 per share

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 third-quarter 2023 dividend on the company’s common stock, payable September 5, 2023, to holders of the Common Stock of record at the close of business on July 28, 2023. The third-quarter 2023 cash dividend will be the 339th consecutive quarterly dividend paid by Pfizer.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Category: Finance

Contacts

Media Contact:
PfizerMediaRelations@Pfizer.com
+1 (212) 733-1226

Investor Contact:
IR@Pfizer.com
+1 (212) 733-4848

Pfizer Inc.

NYSE:PFE

Release Versions

Contacts

Media Contact:
PfizerMediaRelations@Pfizer.com
+1 (212) 733-1226

Investor Contact:
IR@Pfizer.com
+1 (212) 733-4848

More News From Pfizer Inc.

Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:00 a.m. EST on Tuesday, December 16, 2025. The purpose of the call is to provide Pfizer’s full-year 2026 financial guidance. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning tod...

U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer

NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), as neoadjuvant treatment and then continued after cystectomy...

Pfizer Completes Acquisition of Metsera

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. “This strategic milestone represents more than a transaction—it's a deliberate investment in the future of medicine. By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth ther...
Back to Newsroom